A major breakthrough in dementia research has been reported, 40 years in the making.
Dementia Researchers at Sydney’s St Vincent’s Hospital, have discovered that the nerve cell connections responsible for restoring memory, can not only be preserved, but restored. At the same time, they’ve found it’s not necessary to remove plaque, which has long thought to be the cause of Alzheimer’s.
Professor Bryce Vissel says it’s a huge discovery, and their next step is working out how to make the ‘molecular switch’ in humans.
“The next step for us now is to take this discovery, and use it to develop drugs that we know, or believe, will be very effective for patients with Alzheimer’s disease,” said Professor Vissel.
Link: https://www.abc.net.au/news/2023-09...understanding-of-alzheimers-disease/102915132
PS: This is a different approach altogether. The current Clarity AD trials use the drug, Lecanemab, a monoclonal antibody that works by binding to a key protein linked to the malady, called amyloid-beta, and removing it from the body. The Gold Standard for diagnosing Alzheimer’s disease is identifying amyloid beta plaques and tau neurofibrillary tangles.
Even though Amyloid beta removal has an effect on the disease itself it's not proven that it will cure the disease.
Not much details are known about Prof Vissel's study but should be available pretty soon.
Dementia Researchers at Sydney’s St Vincent’s Hospital, have discovered that the nerve cell connections responsible for restoring memory, can not only be preserved, but restored. At the same time, they’ve found it’s not necessary to remove plaque, which has long thought to be the cause of Alzheimer’s.
Professor Bryce Vissel says it’s a huge discovery, and their next step is working out how to make the ‘molecular switch’ in humans.
“The next step for us now is to take this discovery, and use it to develop drugs that we know, or believe, will be very effective for patients with Alzheimer’s disease,” said Professor Vissel.
Link: https://www.abc.net.au/news/2023-09...understanding-of-alzheimers-disease/102915132
PS: This is a different approach altogether. The current Clarity AD trials use the drug, Lecanemab, a monoclonal antibody that works by binding to a key protein linked to the malady, called amyloid-beta, and removing it from the body. The Gold Standard for diagnosing Alzheimer’s disease is identifying amyloid beta plaques and tau neurofibrillary tangles.
Even though Amyloid beta removal has an effect on the disease itself it's not proven that it will cure the disease.
Not much details are known about Prof Vissel's study but should be available pretty soon.
බොහොම ස්තූතියි සහෝ ඔයාටත්, වෛද්ය ක්ෂේත්රෙට සම්බන්ධ අලුත්ම තොරතුරු අපිට දැනගන්න හැමදාමත්ම වගේ ගේනවට.
